An mRNA SARS-CoV‑2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR‑9 Agonist Induces Neutralizing Antibodies and T Cell Memory

• Ole A. W. Haabeth,
• Julian J. K. Lohmeyer,
• Adrienne Sallets,
• Timothy R. Blake,
• Idit Sagiv-Barfi,
• Debra K. Czerwinski,
• Blaine McCarthy,
• Abigail E. Powell,
• Paul A. Wender,
• Robert M. Waymouth,
• Ronald Levy

Affiliations

Ole A. W. Haabeth

Stanford Cancer Institute, Division of Oncology, Department of Medicine, Stanford University, Stanford, California, United States

Julian J. K. Lohmeyer

Stanford Cancer Institute, Division of Oncology, Department of Medicine, Stanford University, Stanford, California, United States

Adrienne Sallets

Stanford Cancer Institute, Division of Oncology, Department of Medicine, Stanford University, Stanford, California, United States

Timothy R. Blake

Stanford Cancer Institute, Division of Oncology, Department of Medicine, Stanford University, Stanford, California, United States

Idit Sagiv-Barfi

Stanford Cancer Institute, Division of Oncology, Department of Medicine, Stanford University, Stanford, California, United States

Debra K. Czerwinski

Stanford Cancer Institute, Division of Oncology, Department of Medicine, Stanford University, Stanford, California, United States

Blaine McCarthy

Department of Chemistry, Stanford University, Stanford, California, United States

Abigail E. Powell

Department of Biochemistry & Stanford ChEM-H, Stanford University, Stanford, California, United States

Paul A. Wender

Department of Chemistry, Stanford University, Stanford, California, United States

Robert M. Waymouth

Department of Chemistry, Stanford University, Stanford, California, United States

Ronald Levy

Stanford Cancer Institute, Division of Oncology, Department of Medicine, Stanford University, Stanford, California, United States